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In this issue, four articles relevant to psoriasis pathogenesis
are published. In one, Kauffman et al (2004) describe initial
favorable clinical responses in a phase 1 study using a hu-
man anti-interleukin (IL)-12 p40 antibody. IL-12 is a het-
erodimeric cytokine consisting of p35 and p40 subunit
proteins. IL-23, a related heterodimeric protein, consists of
p19 and p40 subunits. Thus, a human antibody directed
against p40 (as used in the newly published study) effec-
tively blocks the actions of both IL-12 and IL-23. Interest-
ingly, IL-12 and IL-23 are both produced by activated
(mature) dendritic cells and are critical in promoting differ-
entiation and proliferation of type 1 cytokine-producing
naı¨ve and memory T cells, respectively. As elaborated fur-
ther in the accompanying commentary (Nestle and Conrad,
2004), all of the following are found in excess in lesional
psoriatic skin: (1) activated dendritic cells; (2) IL-23 and (less
so) IL-12; and (3) type 1 cytokine-producing CD4þ and
CD8þ memory T cells. Thus, the p40 subunit of IL-23/IL-12
is an attractive therapeutic target in psoriasis. Indeed, the
paper by Kauffman and colleagues shows evidence that an
anti-p40 antibody has concentration-dependent therapeutic
activity in patients with psoriasis, although much additional
work will be necessary to bring this new drug to the clinic.
Importantly, the paper is noteworthy in the field of psoriasis
pathogenesis in that it is the first to selectively target
cytokines in humans that are produced almost exclusively
by activated dendritic cells. With so much emphasis on the
role of T cells and psoriasis, it is refreshing to see targeting
of more ‘‘upstream’’ molecules, i.e., molecules that may in-
itially be causing T cells to proliferate in the skin of patients
with psoriasis. For additional reading on how dendritic cells
and T cells may be interacting to result in the formation of
psoriatic plaques, the reader is referred to an excellent re-
cent review on the topic by Krueger and colleagues (Lew
et al, 2004).
In a third paper on psoriasis pathogenesis published in
this issue, Alessandrini et al describe abnormalities in en-
zymes involved in lipid formation in the stratum corneum of
patients with psoriasis (Alessandrini et al, 2004). Lamellar
sheets of lipids within the stratum corneum contain ceram-
ides, cholesterol, and free fatty acids, which are essential
in regulating epidermal permeability to water and water-
soluble material. Ceramides are generated by degradation
of glucosylceramides by glucosylceramide-b-glucosidase
and by hydrolysis of sphingomyelin by sphingomyelinase.
Based upon previous work that showed increased trans-
epidermal water loss and abnormal epidermal lipid lamellae
in lesional psoriatic skin, Alessandrini and colleagues quan-
tified mRNA and protein levels of glucosylceramide-b-
glucosidase in lesional and non-lesional skin of patients
with psoriasis. Somewhat surprisingly, they found that
glucosylceramide-b-glucosidase was decreased in non-les-
ional skin, whereas glucosylceramide-b-glucosidase was
increased in lesional skin. Interestingly, these results sug-
gest that decreased ceramide formation (secondary to de-
creased glucosylceramide-b-glucosidase) may contribute
to subtle defects in epidermal barrier function in non-les-
ional skin of psoriatics. Theoretically, this may make non-
lesional psoriatic skin more susceptible to a wide variety of
epicutaneous antigens that may then trigger formation of
psoriatic lesions. If disease occurs, Alessandrini et al assert
that excess production of glucosylceramide-b-glucosidase,
as they document in lesional skin, occurs as a compen-
satory response in an attempt to repair damaged skin.
Although more work is needed to understand the bio-
chemistry of epidermal lipids in patients with psoriasis, this
new manuscript offers potential clues as to how non-les-
ional skin of patients with psoriasis may be particularly
susceptible to epicutaneous antigen exposure.
Ellis et al (2000) published a report showing that trog-
litazone improved psoriasis. Troglitazone belongs to a class
of drugs called the thiazolidinediones that are selective lig-
and agonists of peroxisome proliferator-activated receptor-
gamma (PPARg), a major transcription factor that belongs to
the nuclear receptor superfamily. Although not explicitly a
paper on psoriasis pathogenesis, He et al (2004) describe
in this issue how troglitazone inhibits keratinocyte prolifer-
ation. Interestingly, they describe inhibition of cyclin D1
(a major cell cycle promoting protein) and subsequent in-
hibition of cell cycling in keratinocytes treated with trog-
litazone. Furthermore, in a somewhat surprising finding,
troglitazone’s effects on inhibiting the keratinocyte cell cycle
are described as occurring independently of PPARg signa-
ling. Although the paper is presented with an eye toward
how troglitazone could potentially be used to treat skin
cancers, I viewed them as additional evidence on how
troglitazone may be working when used to treat patients
with psoriasis.
As this Issue of JID amply demonstrates, the molec-
ular and cellular mechanisms underlying the pathogenesis
of psoriasis continue to unfold. Undoubtedly, many addi-
tional clues regarding psoriasis pathogenesis will continue
to be revealed by subsequent well-performed research.
Hopefully, this body of work will someday lead to the dis-
covery of the basic essential defect or defects that cause
psoriasis.
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